Efficacy, Safety, and Immunogenicity Comparison of GME751 Versus EU-Authorized Pembrolizumab in Treatment-Naïve Metastatic Non-Small-Cell Lung Cancer Patients

The primary objective of this study is to compare the **efficacy**, **safety**, and **immune response** of GME751 with EU-authorized Keytruda in adult participants with untreated **metastatic non-small-cell lung cancer**. This comparison is clinically relevant as it aims to determine whether GME751 offers a comparable or superior therapeutic benefit, which could influence treatment decisions and improve patient outcomes in this population.

The clinical trial involves a total of **631 participants** diagnosed with **non-small-cell lung cancer**. The study population includes both male and female subjects, with an age range that spans from young adults to older adults. Participants were selected to ensure a diverse representation of the general population, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The selection process aimed to encompass a broad demographic to enhance the applicability of the trial findings across different segments of the population.

The clinical trial is designed to evaluate the **efficacy**, safety, and immune response of GME751 compared to EU-authorized Keytruda in adult participants with untreated **metastatic lung cancer**, specifically focusing on **non-small-cell lung cancer**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know which treatment is being administered, thus minimizing bias. The estimated duration of the trial spans from the recruitment start date on June 7, 2024, to the anticipated end date on September 21, 2026.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to confirm the diagnosis of non-small-cell lung cancer and ensure that participants meet all inclusion criteria while not falling under any exclusion criteria. Following successful screening, participants will be randomly assigned to receive either GME751 or Keytruda. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess treatment efficacy, and record any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the study investigators. The trial aims to provide valuable insights into the comparative effectiveness of the investigational product and the standard treatment, contributing to the advancement of therapeutic options for non-small-cell lung cancer.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these treatments cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is not provided in the data. As such, these details cannot be elaborated upon in this context.

The clinical trial is scheduled to commence recruitment on June 7, 2024, with an estimated completion date of September 21, 2026. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's efficacy and safety in a larger population. Efficacy assessments will be conducted throughout the trial period, although specific parameters or endpoints for evaluating efficacy, such as symptom improvement scores or biomarker levels, are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters, as well as any tools or instruments involved, are not specified. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy data collected.